Martin Wolf, Robert Shiller and a tough week for biotechs

Episode Summary

Executive Summary: The episode blends FT podcast housekeeping with substantive discussion on economics and markets. Martin Wolf argues crises, inequality and low demand have undermined growth and stability; David Crowe explains Hillary Clinton’s drug-price intervention and its market shock; Robert Schiller and George Akerlof’s “phishing” framework criticizes manipulation in markets and calls for civil-society and regulatory responses. A brief feedback segment closes the show.

Main Topics: Podcast format changes and new spin-off (Priority: 4/5): The hosts announce that Alpha Chat will shorten to 30–40 minutes and launch a longer companion show, Alpha Chatterbox, for deeper economics and business interviews. Martin Wolf on economics, values, and crisis (Priority: 5/5): Wolf explains how his family background, anti-fanatical liberal values, and experience of the Depression, WWII, and 2008 shaped his view that economics should prevent instability and defend democracy. Weak demand, weak supply, and post-crisis stagnation (Priority: 5/5): Wolf argues that demand shortfalls and collapsing investment can permanently reduce potential output, making recessions not just cyclical but structurally damaging. Hillary Clinton, drug pricing, and biotech stocks (Priority: 4/5): FT reporter David Crowe details how Hillary Clinton’s pledge to crack down on prescription drug costs, combined with outrage over Turing Pharmaceuticals’ Daraprim price hike, hit biotech shares. Robert Schiller and George Akerlof’s 'phishing' critique (Priority: 5/5): Schiller describes phishing as broad-based manipulation and deception in markets, from consumer branding to financial products, and argues that free markets often need civil-society and regulatory pushback. Listener feedback and editorial reflection (Priority: 3/5): A follow-up segment revisits previous episodes, especially the rise of internet stars and the Fed/inflation debate, highlighting the show’s attempt to balance theory with accessibility.

Key Arguments: Wolf argues that economics matters most as a tool to prevent catastrophic instability like the Great Depression and 2008. Wolf says his father's anti-fanatical, pro-enlightenment values led him to defend democracy, freedom, welfare-state social democracy, and the 'median' or middle way. Wolf contends that post-1980 globalization brought benefits but also rising inequality, plutocracy, insecurity, and populism, especially after financial liberalization. Wolf argues the recession caused weak demand and weak investment, which in turn damaged innovation and long-run productive capacity, creating a 'vicious circle.' Wolf says unemployment can look healthy while living standards and potential output remain impaired because low productivity growth masks underlying weakness. Crowe explains that Clinton's drug-pricing comments amplified concerns after the Daraprim price jump from $13.50 to $750, helping wipe tens of billions off biotech valuations. Crowe argues pharma needs a 'grand bargain': stop overnight price gouging on old drugs while preserving incentives and returns for genuine innovation. Schiller argues that manipulation is often systemic rather than individual moral failure; firms fish because competitors do, margins are tight, and the market rewards it. Schiller says 'caveat emptor' can invite abuse if buyers are not protected from gray-area deception, so regulators and civil society must set boundaries. Schiller and Akerlof frame the solution as a mix of informed public pressure, targeted regulation, and non-authoritarian nudges rather than market abolition.

Data Points: Podcast length change: 30–40 minutes - Alpha Chat will be shortened from about an hour to roughly 30–40 minutes. New companion podcast: Alpha Chatterbox - A new show is being spun off for longer, wonkier business and economics conversations. Martin Wolf interview length: 90 minutes - The excerpt comes from a longer interview recorded for the new podcast. Book length: 350 pages - Wolf says a book needs to interest readers across roughly 350 pages of dense analysis. Economy at risk: Very close to collapse - Wolf says the 2008 financial crisis brought the global economy close to collapse. Comparative output gap: About a sixth below pre-crisis trend - Wolf says actual output in the U.S. and U.K. remains far below pre-crisis expectations. Biotech market value hit: About $38 billion wiped off - Crowe says investors sold biotech stocks after Clinton’s tweet on drug pricing. Daraprim price increase: $13.50 to $750 - Turing Pharmaceuticals raised the price of the drug dramatically, triggering outrage. Out-of-pocket cap proposal: $250 a month - Crowe cites one element of Clinton’s plan for chronically ill patients. FTC/advertising concern: Wall-to-wall pharmaceutical commercials - Crowe notes that U.S. TV is saturated with drug advertising, a target of reform proposals. Phishing example scale: 900 outlets - Schiller cites Cinnabon’s global footprint as an example of successful demand-manipulation. Mentioned macro timing: September/October 2008 - Wolf identifies the key phase of the financial crisis when collapse risk became clear.

Pivotal Quotes: "Authority is, I think, worthless. You have to provide evidence and arguments." — Martin Wolf: Wolf explains why his columns focus on analysis rather than personal authority. "Weak demand caused weak supply as a result of low investment, and weak growth caused weak demand. Again, principally as a result of the weakness of investment. This, then, was a vicious circle." — Martin Wolf: His core argument about how recessions can permanently damage potential output. "A fishing equilibrium comes when everybody has got away with as much manipulation as they can get away with." — Robert Schiller: Schiller defines how manipulation becomes normalized in markets.

Implications: The episode argues that markets do not self-correct cleanly: crises can scar growth, drug pricing can trigger political and market backlash, and consumer/financial manipulation may require smarter regulation, civil society pressure, and careful policy design.